Exactech Receives a Hold from Robert W. Baird

By Jason Carr

In a report issued on December 4, Jeff Johnson from Robert W. Baird reiterated a Hold rating on Exactech (NASDAQ: EXAC), with a price target of $49. The company’s shares closed yesterday at $50.55, close to its 52-week high of $50.95.

According to TipRanks.com, Johnson is a 4-star analyst with an average return of 8.1% and a 58.0% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Zimmer Biomet Holdings, and Wright Medical Group.

Exactech has an analyst consensus of Hold, with a price target consensus of $49.

Based on Exactech’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $61.4 million and quarterly net profit of $2.86 million. In comparison, last year the company earned revenue of $59.92 million and had a net profit of $3.17 million.

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exactech, Inc. develops, manufactures, markets, distributes, and sells orthopedic implant devices; related surgical instrumentation; and biologic services to hospitals and physicians. It also engages in the sale and distribution of joint replacement systems.